Contineum Therapeutics, Inc. - 8-K Filing

Contineum Therapeutics updated its corporate presentation to reflect business and strategic updates, including clinical progress on lead programs. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $CTNM

Read the full article at SEC EDGAR

More Regulatory news